Patents by Inventor Wieslaw Adam Mazur

Wieslaw Adam Mazur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140179875
    Abstract: Described herein are novel solid-supported sulfurization reagents having the general structure: (I) wherein (P) is a polymer; X is a linker; R1 is an alkyl group, a cycloalkyl group, an aryl group, or a heterocycle; and R2 is an alkyl group, an aryl group, a methyleneacyloxy group having the formula —CH2—O—C(O)—R7, a methylene carbonate group having the formula —CH2—O—C(O)—OR8, or a methylene carbamate group having the formula —CH2—O—C(O)—NR9R10, wherein R7 is a C1 to C20 hydrocarbon residue, R8 is any alkyl, cycloalkyl, aryl, or heteroaryl, and R9 and R10 are independently hydrogen, alkyl, cycloalkyl, aryl, or heteroaryl. Other embodiments include solid-supported sulfurization reagents having the structure of Formula I, wherein (P) is a polystyrene-based solid support and X is an aromatic linker. Also described herein are methods for synthesizing the solid-supported sulfurization reagents and their use during the synthesis of oligonucleotides.
    Type: Application
    Filed: July 24, 2012
    Publication date: June 26, 2014
    Applicant: GIRINDUS AMERICA, INC.
    Inventors: Wieslaw Adam Mazur, Victor Sorokin, Steven Karl Laughlin
  • Patent number: 8710210
    Abstract: A method for synthesizing an oligonucleotide which comprises using a sulfurizing agent of general formula (I) for sulfurizing at least one phosphorus internucleotide linkage of a precursor of the oligonucleotide, wherein R is an aryl group or a heteroaryl group, which is bonded to the S-atom through an annular carbon atom; and R1 and R2 are independently organic residues, preferably a C1-C20 hydrocarbon residue. The method may further comprise purifying the oligonucleotide. Also included is a process for the synthesis of the sulfurizing agent.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: April 29, 2014
    Assignee: Girindus America, Inc.
    Inventors: Yigang He, Victor Sorokin, Wieslaw Adam Mazur
  • Patent number: 8586973
    Abstract: The present invention relates to a host material comprising a compound having two carbazole moieties which is suitable for blue-emitting OLEDs. Surprisingly, it has been found that when appropriate substituents are present in the carbazole structure, the solubility of the compounds can be improved without any adverse effect on the OLED performance. The present invention further relates to the use of the host materials and to an organic light emitting device comprising the host material.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: November 19, 2013
    Assignee: Solvay SA
    Inventors: Roland Martin, Veronique Mathieu, Victor Sorokin, Praveen Bachawala, Wieslaw Adam Mazur, Jonathan Maunoury
  • Publication number: 20130096291
    Abstract: A method for synthesizing an oligonucleotide which comprises using a sulfurizing agent of general formula (I) for sulfurizing at least one phosphorus internucleotide linkage of a precursor of the oligonucleotide, wherein R is an aryl group or a heteroaryl group, which is bonded to the S-atom through an annular carbon atom; and R1 and R2 are independently organic residues, preferably a C1-C20 hydrocarbon residue. The method may further comprise purifying the oligonucleotide. Also included is a process for the synthesis of the sulfurizing agent.
    Type: Application
    Filed: June 30, 2011
    Publication date: April 18, 2013
    Applicant: GIRINDUS AMERICA, INC.
    Inventors: Yigang He, Victor Sorokin, Wieslaw Adam Mazur
  • Publication number: 20120071640
    Abstract: An oligonucleotide which comprises at least one internucleotide linkage comprising a P—S—R bond and at least two nucleosides, wherein R corresponds to the formula (I) wherein A is a geminally substituted alkylene group, preferably CH2, X and Y are independently selected from S and O, and R0 is selected from the group consisting of optionally substituted carbon bonded organic residue, such as in particular optionally substituted alkyl or aryl, SRx, ORx and NRxRy wherein Rx and/or Ry are selected from H and organic residues and at least Rx is a substituent other than H. Another object of the invention is a sulfurizing agent useful for oligonucleotide manufacture and the manufacture thereof.
    Type: Application
    Filed: June 22, 2011
    Publication date: March 22, 2012
    Applicant: GIRINDUS AMERICA, INC.
    Inventors: Wieslaw Adam MAZUR, Yigang HE, Victor D. SOROKIN
  • Publication number: 20110260149
    Abstract: The present invention relates to a host material comprising a compound having a carbazole moiety which is suitable for blue-emitting OLEDs. Surprisingly, it has been found that when appropriate substituents are present in the carbazole structure, the solubility of the compounds can be improved without any adverse effect on the OLED performance. The present invention further relates to the use of the host materials and to an organic light emitting device comprising the host material.
    Type: Application
    Filed: October 15, 2009
    Publication date: October 27, 2011
    Applicant: SOLVAY SA
    Inventors: Roland Martin, Veronique Mathieu, Victor Sorokin, Praveen Bachawala, Wieslaw Adam Mazur
  • Publication number: 20110198579
    Abstract: The present invention relates to a host material comprising a compound having two carbazole moieties which is suitable for blue-emitting OLEDs. Surprisingly, it has been found that when appropriate substituents are present in the carbazole structure, the solubility of the compounds can be improved without any adverse effect on the OLED performance. The present invention further relates to the use of the host materials and to an organic light emitting device comprising the host material.
    Type: Application
    Filed: October 15, 2009
    Publication date: August 18, 2011
    Applicant: SOLVAY SA
    Inventors: Roland Martin, Veronique Mathieu, Victor Sorokin, Praveen Bachawala, Wieslaw Adam Mazur, Jonathan Maunoury
  • Patent number: 7897731
    Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: March 1, 2011
    Assignee: Warner Chilcott Company, LLC
    Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur
  • Publication number: 20100244012
    Abstract: The present invention relates to anthracene derivative compounds represented by Formula I: or a pharmaceutically acceptable salt thereof, with R1, R2, R3, R4, L, X, a, b, and c defined herein. The compounds of the present invention, having a substituted silicon atom introduced in anthracene, advantageously improve the solubility of anthracene without any adverse effects, thereby allowing solvent-processing. Also disclosed are light emitting materials comprising such compounds, the use of such light emitting materials, and organic light emitting devices comprising such light emitting materials.
    Type: Application
    Filed: December 18, 2008
    Publication date: September 30, 2010
    Applicant: SOLVAY (SOCIETE ANONYME)
    Inventors: Wieslaw Adam Mazur, Angelina Tsenova Georgieva
  • Publication number: 20100197579
    Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
    Type: Application
    Filed: October 26, 2009
    Publication date: August 5, 2010
    Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur
  • Patent number: 7632933
    Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: December 15, 2009
    Assignee: The Procter & Gamble Company
    Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur
  • Patent number: 7612080
    Abstract: The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: November 3, 2009
    Assignee: Cincinnati Children's Hospital Medical Center
    Inventors: Yi Zheng, Huzoor Akbar, David A. Williams, Wieslaw Adam Mazur
  • Patent number: 7608701
    Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: October 27, 2009
    Assignee: The Procter & Gamble Company
    Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur
  • Publication number: 20090124793
    Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
    Type: Application
    Filed: February 2, 2007
    Publication date: May 14, 2009
    Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur
  • Patent number: 7462597
    Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
    Type: Grant
    Filed: May 4, 2005
    Date of Patent: December 9, 2008
    Assignee: The Procter & Gamble Company
    Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur
  • Patent number: 7192924
    Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: March 20, 2007
    Assignee: The Procter & Gamble Company
    Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur
  • Patent number: 7192923
    Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: March 20, 2007
    Assignee: The Procter & Gamble Company
    Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur
  • Patent number: 7132539
    Abstract: The present invention relates to compounds which comprise a nitrogen-containing ring scaffold substituted by an R1 alkyl units selected from the group consisting of C1–C12 linear or branched alkyl, C3–C8 cyclic alkyl, C2–C12 linear or branched alkenyl, or haloalkyl, for example, the 2-keto-3-alkylpiperazines having the formula: wherein R is selected from the group consisting of phenyl, 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl, and 4-chlorophenyl; R1 is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, benzyl, allyl, 1-methylallyl, 2-methylallyl, but-2-enyl, and propargyll; R7a is selected from the group consisting of hydrogen, —CO2H, —CONH2, —CONHCH3, and —CON(CH3)2; R8 is benzyl, substituted benzyl, or naphthalen-2-ylmethyl.
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: November 7, 2006
    Assignee: The Procter & Gamble Company
    Inventors: Frank Hallock Ebetino, Xinrong Tian, Wieslaw Adam Mazur, Anny-Odile Colson
  • Patent number: 7087759
    Abstract: Disclosed are MC-3/MC-4 receptor ligands, the ligands having the following formula: wherein A is a conformationally restricted ring system selected from the group consisting of: a) non-aromatic carbocyclic rings; b) aromatic carbocyclic rings; c) non-aromatic heterocyclic rings; d) aromatic heterocyclic rings; wherein said rings comprises from 5 to 8 atoms; and W is a unit which preferable comprises D-1-fluorophenyalanine, Y comprises a heteroatom, and Z comprises an aromatic carbocyclic ring. Also disclosed are pharmaceutical compositions comprising the ligands of the invention as well as methods of treating diseases mediated through MC-3/MC-4 receptors.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: August 8, 2006
    Assignee: The Procter & Gamble Company
    Inventors: Wieslaw Adam Mazur, Xinrong Tian, Xiufeng Eric Hu, Frank Hallock Ebetino
  • Patent number: 6936585
    Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: August 30, 2005
    Assignee: The Procter & Gamble Company
    Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur